- patients with severe renal impairment, including those receiving dialysis[see CLINICAL PHARMACOLOGY (12.3)].
- patients with active liver disease, including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities [see WARNINGS AND PRECAUTIONS (5.3)].
- patients with preexisting gallbladder disease [see WARNINGS AND PRECAUTIONS (5.5)].
- nursing mothers [see USE IN SPECIFIC POPULATIONS (8.2)].
- patients with hypersensitivity to fenofibric acid or fenofibrate[see WARNINGS AND PRECAUTIONS (5.9)].
Fenofibric acid is the active metabolite of fenofibrate. Adverse events reported by 2% or more of patients treated with fenofibrate and greater than placebo during double-blind, placebo-controlled trials are listed in Table 1. Adverse events led to discontinuation of treatment in 5.0% of patients treated with fenofibrate and in 3.0% treated with placebo. Increases in liver tests were the most frequent events, causing discontinuation of fenofibrate treatment in 1.6% of patients in double-blind trials.
Table 1. Adverse Events Reported by 2% or More of Patients Treated with Fenofibrate and Greater than Placebo During the Double-Blind, Placebo-Controlled TrialsBODY SYSTEM Adverse Event
| Fenofibrate Dosage equivalent to 135 mg fenofibric acid (N = 439)
| Placebo (N = 365)
|
BODY AS A WHOLE
|
|
|
Abdominal Pain
| 4.6%
| 4.4%
|
Back Pain
| 3.4%
| 2.5%
|
Headache
| 3.2%
| 2.7%
|
DIGESTIVE
|
|
|
Nausea
| 2.3%
| 1.9%
|
Constipation
| 2.1%
| 1.4%
|
INVESTIGATIONS
|
|
|
Abnormal Liver Tests
| 7.5%
| 1.4%
|
Increased AST
| 3.4%
| 0.5%
|
Increased ALT
| 3.0%
| 1.6%
|
Increased Creatine Phosphokinase
| 3.0%
| 1.4%
|
RESPIRATORY
|
|
|
Respiratory Disorder
| 6.2%
| 5.5%
|
Rhinitis
| 2.3%
| 1.1%
|
Urticaria was seen in 1.1% vs. 0%, and rash in 1.4% vs. 0.8% of fenofibrate and placebo patients respectively in controlled trials.
Clinical trials with fenofibric acid did not include a placebo-control arm. However, the adverse event profile of fenofibric acid was generally consistent with that of fenofibrate. The following adverse events not listed above were reported in ≥ 3% of patients taking fenofibric acid alone:
Gastrointestinal Disorders:
Diarrhea, dyspepsia
General Disorders and Administration Site Conditions:
Pain
Infections and Infestations:
Nasopharyngitis, sinusitis, upper respiratory tract infection
Musculoskeletal and Connective Tissue Disorders:
Arthralgia, myalgia, pain in extremity
Nervous System Disorders:
Dizziness
Specific Populations
Geriatrics :
In five elderly volunteers 77 to 87 years of age, the oral clearance of fenofibric acid following a single oral dose of fenofibrate was 1.2 L/h, which compares to 1.1 L/h in young adults. This indicates that an equivalent dose of fenofibric acid delayed-release capsules can be used in elderly subjects with normal renal function, without increasing accumulation of the drug or metabolites [see USE IN SPECIFIC POPULATIONS (8.5)].
Pediatrics:
The pharmacokinetics of fenofibric acid has not been studied in pediatric populations.
Gender:
No pharmacokinetic difference between males and females has been observed for fenofibric acid delayed-release capsules.
Race:
The influence of race on the pharmacokinetics of fenofibric acid delayed-release capsules has not been studied; however, fenofibric acid is not metabolized by enzymes known for exhibiting inter-ethnic variability.
Renal Impairment:
The pharmacokinetics of fenofibric acid was examined in patients with mild, moderate, and severe renal impairment. Patients with severe renal impairment (estimated glomerular filtration rate [eGFR] <30 mL/min/1.73m2) showed a 2.7-fold increase in exposure for fenofibric acid and increased accumulation of fenofibric acid during chronic dosing compared to that of healthy subjects. Patients with mild to moderate renal impairment (eGFR 30 to 59 mL/min/1.73m2) had similar exposure but an increase in the half-life for fenofibric acid compared to that of healthy subjects. Based on these findings, the use of fenofibric acid delayed-release capsules should be avoided in patients who have severe renal impairment and dose reduction is required in patients having mild to moderate renal impairment [see DOSAGE AND ADMINISTRATION (2.4)].
Hepatic Impairment:
No pharmacokinetic studies have been conducted in patients with hepatic impairment.
Drug-drug Interactions
In vitro studies using human liver microsomes indicate that fenofibric acid is not an inhibitor of cytochrome (CYP) P450 isoforms CYP3A4, CYP2D6, CYP2E1, or CYP1A2. It is a weak inhibitor of CYP2C8, CYP2C19, and CYP2A6, and mild-to-moderate inhibitor of CYP2C9 at therapeutic concentrations.
Comparison of atorvastatin exposures when atorvastatin (80 mg once daily for 10 days) is given in combination with fenofibric acid (Fenofibric acid delayed-release capsules 135 mg once daily for 10 days) and ezetimibe (10 mg once daily for 10 days) versus when atorvastatin is given in combination with ezetimibe only (ezetimibe 10 mg once daily and atorvastatin, 80 mg once daily for 10 days): The Cmax decreased by 1 % for atorvastatin and ortho-hydroxy- atorvastatin and increased by 2% for parahydroxy-atorvastatin. The AUC decreased 6% and 9% for atorvastatin and orthohydroxy-atorvastatin, respectively, and did not change for para-hydroxy-atorvastatin.
Comparison of ezetimibe exposures when ezetimibe (10 mg once daily for 10 days) is given in combination with fenofibric acid (Fenofibric acid delayed-release capsules 135 mg once daily for 10 days) and atorvastatin (80 mg once daily for 10 days) versus when ezetimibe is given in combination with atorvastatin only (ezetimibe 10 mg once daily and atorvastatin, 80 mg once daily for 10 days): The Cmax increased by 26% and 7% for total and free ezetimibe, respectively. The AUC increased by 27% and 12% for total and free ezetimibe, respectively.
Table 2 describes the effects of co-administered drugs on fenofibric acid systemic exposure. Table 3 describes the effects of co-administered fenofibric acid on other drugs.
Table 2. Effects of Co-Administered Drugs on Fenofibric Acid Systemic Exposure from Fenofibric Acid Delayed-Release Capsules or Fenofibrate Administration Co-Administered Drug
| Dosage Regimen of Co-Administered Drug
| Dosage Regimen of Fenofibric Acid Delayed-Release Capsules or Fenofibrate
| Changes in Fenofibric Acid Exposure
|
|
|
| AUC
| Cmax
|
Lipid-lowering agents
|
Rosuvastatin
| 40 mg once daily for 10 days
| Fenofibric acid delayed-release capsules 135 mg once daily for 10 days
| ↓2%
| ↓2%
|
Atorvastatin
| 20 mg once daily for 10 days
| Fenofibrate 160 mg TriCor (fenofibrate) oral tablet once daily for 10 days
| ↓2%
| ↓4%
|
Atorvastatin + ezetimibe
| Atorvastatin, 80 mg once daily and ezetimibe, 10 mg once daily for 10 days
| Fenofibric acid delayed-release capsules 135 mg once daily for 10 days
| ↑5%
| ↑5%
|
Pravastatin
| 40 mg as a single dose
| Fenofibrate 3 x 67 mg TriCor (fenofibrate) oral micronized capsule as a single dose
| ↓1%
| ↓2%
|
Fluvastatin
| 40 mg as a single dose
| Fenofibrate 160 mg as a single dose
| ↓2%
| ↓10%
|
Simvastatin
| 80 mg once daily for 7 days
| Fenofibrate 160 mg once daily for 7 days
| ↓5%
| ↓11%
|
Anti-diabetic agents
|
Glimepiride
| 1 mg as a single dose
| Fenofibrate 145 mg once daily for 10 days
| ↑1%
| ↓1%
|
Metformin
| 850 mg 3 times daily for 10 days
| Fenofibrate 54 mg 3 times daily for 10 days
| ↓9%
| ↓6%
|
Rosiglitazone
| 8 mg once daily for 5 days
| Fenofibrate 145 mg once daily for 14 days
| ↑10%
| ↑3%
|
Gastrointestinal agents
|
Omeprazole
| 40 mg once daily for 5 days
| Fenofibric acid delayed-release capsules 135 mg as a single dose fasting
| ↑6%
| ↑17%
|
Omeprazole
| 40 mg once daily for 5 days
| Fenofibric acid delayed-release capsules 135 mg as a single dose with food
| ↑4%
| ↓2%
|
Table 3. Effects of Fenofibric Acid Delayed-Release Capsules or Fenofibrate Co-Administration on Systemic Exposure of Other DrugsDosage Regimen of Fenofibric Acid Delayed-Release Capsules or Fenofibrate
| Dosage Regimen of Co-Administered Drug
| Change in Co-Administered Drug Exposure
|
|
| Analyte
| AUC
| Cmax
|
Lipid-lowering agents
|
Fenofibric acid delayed-release capsules 135 mg once daily for 10 days
| Rosuvastatin, 40 mg once daily for 10 days
| Rosuvastatin
| ↑6%
| ↑20%
|
| Fenofibrate 160 mg TriCor (fenofibrate) oral tablet once daily for 10 days
| Atorvastatin, 20 mg once daily for 10 days
| Atorvastatin
| ↓17%
| 0%
|
| Fenofibrate 3 x 67 mg TriCor (fenofibrate) oral micronized capsule as a single dose
| Pravastatin, 40 mg as a single dose
| Pravastatin
| ↑13%
| ↑13%
|
|
| 3α-Hydroxyl-isopravastatin
| ↑26%
| ↑29%
|
Fenofibrate 160 mg as a single dose
| Fluvastatin, 40 mg as a single dose
| (+)-3R, 5S-Fluvastatin
| ↑15%
| ↑16%
|
Fenofibrate 160 mg once daily for 7 days
| Simvastatin, 80 mg once daily for 7 days
| Simvastatin acid
| ↓36%
| ↓11%
|
|
| Simvastatin
| ↓11%
| ↓17%
|
|
| Active HMG-CoA Inhibitors
| ↓12%
| ↓1%
|
|
| Total HMG-CoA Inhibitors
| ↓8%
| ↓10%
|
Anti-diabetic agents
|
Fenofibrate 145 mg once daily for 10 days
| Glimepiride, 1 mg as a single dose
| Glimepiride
| ↑35%
| ↑18%
|
Fenofibrate 54 mg 3 times daily for 10 days
| Metformin, 850 mg 3 times daily for 10 days
| Metformin
| ↑3%
| ↑6%
|
Fenofibrate 145 mg once daily for 14 days
| Rosiglitazone, 8 mg once daily for 5 days
| Rosiglitazone
| ↑6%
| ↓1%
|
Read this Medication Guide before you start taking fenofibric acid delayed-release capsules and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.
What is the most important information I should know about Fenofibric Acid Delayed-Release Capsules?
Fenofibric acid delayed-release capsules can cause muscle pain, tenderness or weakness, which may be symptoms of a rare but serious muscle condition called rhabdomyolysis. In some cases rhabdomyolysis can cause kidney damage and death. The risk of rhabdomyolysis may be higher when Fenofibric acid delayed-release capsules are given with statins. If you take a statin, tell your healthcare provider.
What are Fenofibric Acid Delayed-Release Capsules?
Fenofibric acid delayed-release capsules are a prescription medicine used to treat cholesterol in the blood by lowering the total amount of triglycerides and LDL (bad) cholesterol, and increasing the HDL (good) cholesterol. Fenofibric acid delayed-release capsules have not been shown to lower your risk of having heart problems or a stroke. You should be on a low fat and low cholesterol diet while you take fenofibric acid delayed-release capsules.
The safety and effectiveness of fenofibric acid delayed-release capsule in children is not known.
Who should not take Fenofibric Acid Delayed-Release Capsules?
Do not take fenofibric acid delayed-release capsules if you:
- are allergic to fenofibric acid, or any of the ingredients in fenofibric acid delayed-release capsules. See the end of this Medication Guide for a list of all the ingredients in fenofibric acid delayed-release capsules.
- have severe kidney disease
- have liver disease
- have gallbladder disease
- are a nursing mother
Talk to your healthcare provider before you take fenofibric acid delayed-release capsules if you have any of these conditions.
What should I tell my healthcare provider before taking Fenofibric Acid Delayed-Release Capsules?
Before taking fenofibric acid delayed-release capsules, tell your healthcare provider about all your medical conditions, including if you:
- are allergic to any medicines.
- have ever had kidney problems.
- have ever had liver problems.
- have ever had gallbladder problems.
- are pregnant or if you plan to become pregnant. It is not known if fenofibric acid delayed-release capsules will harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if fenofibric acid passes into your breast milk. You and your healthcare provider should decide if you will take fenofibric acid delayed-release capsules or breastfeed. You should not do both.
Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins and herbal supplements.
Using fenofibric acid delayed-release capsules with certain other medicines can affect the way these medicines work and other medicines may affect how fenofibric acid delayed-release capsules works. In some cases, using fenofibric acid delayed-release capsules with other medicines can cause serious side effects.
Know all the medicines you take. Keep a list of them and show it to your healthcare provider when you get a new medicine.
It is especially important to tell your healthcare provider if you take any of the medicines listed below:
- anticoagulants , also known as blood thinners (Warfarin, Coumadin)
- bile acid resins
- cyclosporine
Ask your healthcare provider if you are not sure if your medicine is one of these.
How should I take Fenofibric Acid Delayed-Release Capsules?
- You should be on a low fat and low cholesterol diet while you take fenofibric acid delayed-release capsules.
- Take fenofibric acid delayed-release capsules one time each day as prescribed by your healthcare provider.
- Take fenofibric acid delayed-release capsules with or without food.
- Swallow fenofibric acid delayed-release capsules whole. Do not break, crush, dissolve, or chew fenofibric acid delayed-release capsules before swallowing. If you cannot swallow fenofibric acid delayed-release capsules whole, tell your healthcare provider, you may need a different medicine.
- If you miss a dose of fenofibric acid delayed-release capsules, take it as soon as you remember. If it is almost time for your next dose, just skip the missed dose. Take the next dose at your regular time. If you are not sure about your dosing, call your healthcare provider.Do not take more than one dose of fenofibric acid delayed-release capsules a day unless your healthcare provider tells you to.
- If you take too much fenofibric acid delayed-release capsules, contact your healthcare provider or your local emergency department.
- Do not change your dose or stop fenofibric acid delayed-release capsules unless your healthcare provider tells you to.
- Your healthcare provider may do blood tests before you start taking fenofibric acid delayed-release capsules and during treatment. See your healthcare provider regularly to check your cholesterol and triglyceride levels and to check for side effects.
What are the possible side effects with Fenofibric Acid Delayed-Release Capsules?
Fenofibric acid delayed-release capsules may cause serious side effects, including:
- muscle pain, tenderness, or weakness . See "What is the most important information that I should know about fenofibric acid delayed-release capsules?"
- tiredness and fever
- abdominal pain, nausea, or vomiting . These may be signs of inflammation (swelling) of the gallbladder or pancreas.
Call your healthcare provider right away if you have any of these serious side effects.
The most common side effects with fenofibric acid delayed-release capsules include:
- headache
- heartburn (indigestion)
- nausea
- muscle aches
- increases in muscle or liver enzymes that are measured by blood tests
Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of fenofibric acid delayed-release capsules. For more information, ask your healthcare provider or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How do I store Fenofibric Acid Delayed-Release Capsules?
- Store fenofibric acid delayed-release capsules between 59 to 86° F (15 to 30° C).
- Protect fenofibric acid delayed-release capsules from moisture.
Keep fenofibric acid delayed-release capsules and all medicines out of the reach of children.
General information about the safe and effective use of Fenofibric Acid Delayed-Release Capsules.
Medicines are sometimes prescribed for conditions that are not mentioned in the Medication Guide. Do not use fenofibric acid delayed-release capsules for a condition for which it was not prescribed. Do not give fenofibric acid delayed-release capsules to other people, even if they have the same condition you have. It may harm them.
This Medication Guide summarizes the most important information about fenofibric acid delayed-release capsules. If you would like more information, talk to your healthcare provider. You can also ask your pharmacist or healthcare provider for information that is written for health professionals.
For more information go to www.lupinpharmaceuticals.com or call at 1-800-399-2561.
What are the ingredients in Fenofibric Acid Delayed-Release Capsules?
Active Ingredient: Fenofibric acid
Inactive Ingredients: colloidal silicon dioxide, dibutyl sebacate, ethyl cellulose, hypromellose, lactose monohydrate, magnesium stearate, methacrylic acid co polymer, povidone, sodium stearyl fumarate, talc and triethyl citrate. The capsule shell of the 45 mg capsule contains the following inactive ingredients: gelatin, iron oxide black, iron oxide red, iron oxide yellow, sodium lauryl sulphate and titanium dioxide. The capsule shell of the 135 mg capsule contains the following inactive ingredients: FD and C Blue #1, gelatin, iron oxide yellow, sodium lauryl sulphate and titanium dioxide. The capsules are printed with edible ink containing iron oxide black, potassium hydroxide, propylene glycol and shellac.
* The brands listed are trademarks of their respective owners and are not trademarks of Lupin Pharmaceuticals, Inc. The makers of these brands are not affiliated with and do not endorse Lupin Pharmaceuticals, Inc. or its products.
Manufactured for
Lupin Pharmaceuticals, Inc.
Baltimore, Maryland 21202
United States
Manufactured by:
Lupin Limited
Goa - 403 722
INDIA
Revised: June 15, 2015 ID#: 241784